Literature DB >> 12010965

Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.

Angus J MacDonald1, Prasad S D Turaga, Carolyn Harmon-Brown, Tracy J Tierney, Kristine E Bennett, Maggie C McCarthy, Scott C Simonek, Peter A Enyong, Daniel W Moukatte, Sara Lustigman.   

Abstract

The possibility of concomitant immunity and its potential mechanisms in Onchocerca volvulus infection were examined by analyzing cytokine and antibody responses to infective larval (third-stage larvae [L3] and molting L3 [mL3]), adult female worm (F-OvAg), and skin microfilaria (Smf) antigens in infected individuals in a region of hyperendemicity in Cameroon as a function of age. Peripheral blood mononuclear cell interleukin 5 (IL-5) responses to F-OvAg and Smf declined significantly with age (equivalent to years of exposure to O. volvulus). In contrast, IL-5 secretion in response to L3 and mL3 remained elevated with increasing age. Gamma interferon responses to L3, mL3, and F-OvAg were low or suppressed and unrelated to age, except for responses to Smf in older subjects. IL-10 levels were uniformly elevated, regardless of age, in response to L3, mL3, and F-OvAg but not to Smf, for which levels declined with age. A total of 49 to 60% of subjects had granulocyte-macrophage colony-stimulating factor responses to all O. volvulus antigens unrelated to age. Analysis of levels of stage-specific immunoglobulin G3 (IgG3) and IgE revealed a striking, age-dependent dissociation between antibody responses to larval antigens (L3 and a recombinant L3-specific protein, O. volvulus ALT-1) which were significantly increased or maintained with age and antibody responses to F-OvAg, which decreased. Levels of IgG1 to L3 and F-OvAg were elevated regardless of age, and levels of IgG4 increased significantly with age, although not to O. volvulus ALT-1, which may have unique L3-specific epitopes. Immunofluorescence staining of whole larvae showed that total anti-L3 immunoglobulin levels also increased with the age of the serum donor. The separate and distinct cytokine and antibody responses to adult and infective larval stages of O. volvulus which are age related are consistent with the acquisition of concomitant immunity in infected individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010965      PMCID: PMC127981          DOI: 10.1128/IAI.70.6.2796-2804.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  The third-stage larva (L3) of Brugia: its role in immune modulation and protective immunity.

Authors:  E Devaney; J Osborne
Journal:  Microbes Infect       Date:  2000-09       Impact factor: 2.700

2.  Animal models for the study of immunity in human filariasis.

Authors:  J B Lok; D Abraham
Journal:  Parasitol Today       Date:  1992-05

Review 3.  Immunological genomics of Brugia malayi: filarial genes implicated in immune evasion and protective immunity.

Authors:  R M Maizels; M L Blaxter; A L Scott
Journal:  Parasite Immunol       Date:  2001-07       Impact factor: 2.280

Review 4.  Pathogenesis of onchocercal keratitis (River blindness).

Authors:  L R Hall; E Pearlman
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

5.  Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.

Authors:  A A Gbakima; T B Nutman; J E Bradley; L A McReynolds; M D Winget; Y Hong; A L Scott
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

6.  Isotype-specific characterization of antibody responses to Onchocerca volvulus in putatively immune individuals.

Authors:  G R Stewart; L Elson; E Araujo; R Guderian; T B Nutman; J E Bradley
Journal:  Parasite Immunol       Date:  1995-07       Impact factor: 2.280

7.  Early human infection with Onchocerca volvulus is associated with an enhanced parasite-specific cellular immune response.

Authors:  P J Cooper; T Mancero; M Espinel; C Sandoval; R Lovato; R H Guderian; T B Nutman
Journal:  J Infect Dis       Date:  2001-04-27       Impact factor: 5.226

8.  Immunity to onchocerciasis: putative immune persons produce a Th1-like response to Onchocerca volvulus.

Authors:  L H Elson; M Calvopiña; W Paredes; E Araujo; J E Bradley; R H Guderian; T B Nutman
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

9.  Onchocerciasis and immunity in humans: enhanced T cell responsiveness to parasite antigen in putatively immune individuals.

Authors:  D J Ward; T B Nutman; G Zea-Flores; C Portocarrero; A Lujan; E A Ottesen
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

10.  Interleukin-10 and antigen-presenting cells actively suppress Th1 cells in BALB/c mice infected with the filarial parasite Brugia pahangi.

Authors:  J Osborne; E Devaney
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

View more
  22 in total

1.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model.

Authors:  Jessica A Hess; Bin Zhan; Sandra Bonne-Année; Jessica M Deckman; Maria Elena Bottazzi; Peter J Hotez; Thomas R Klei; Sara Lustigman; David Abraham
Journal:  Int J Parasitol       Date:  2014-06-05       Impact factor: 3.981

Review 2.  Onchocerca volvulus: The Road from Basic Biology to a Vaccine.

Authors:  Sara Lustigman; Benjamin L Makepeace; Thomas R Klei; Simon A Babayan; Peter Hotez; David Abraham; Maria Elena Bottazzi
Journal:  Trends Parasitol       Date:  2017-09-22

3.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

4.  In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination.

Authors:  Virginia L Tchakouté; Simon P Graham; Siv Aina Jensen; Benjamin L Makepeace; Charles K Nfon; Leo M Njongmeta; Sara Lustigman; Peter A Enyong; Vincent N Tanya; Albert E Bianco; Alexander J Trees
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

5.  The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.

Authors:  Fidelis Cho-Ngwa; Jing Liu; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24

Review 6.  Acquired immune heterogeneity and its sources in human helminth infection.

Authors:  C D Bourke; R M Maizels; F Mutapi
Journal:  Parasitology       Date:  2010-10-15       Impact factor: 3.234

7.  Relationship between skin snip and Ov16 ELISA: Two diagnostic tools for onchocerciasis in a focus in Cameroon after two decades of ivermectin-based preventive chemotherapy.

Authors:  Linda Djune-Yemeli; André Domché; Hugues C Nana-Djeunga; Cyrille Donfo-Azafack; Cedric G Lenou-Nanga; Palmer Masumbe-Netongo; Joseph Kamgno
Journal:  PLoS Negl Trop Dis       Date:  2022-05-02

8.  Human immune responses to infective stage larval-specific chitinase of filarial parasite, Onchocerca volvulus, Ov-CHI-1.

Authors:  Yang Wu; Gillian Egerton; James S McCarthy; Thomas B Nutman; Albert E Bianco
Journal:  Filaria J       Date:  2003-03-14

9.  Early Decision: Effector and Effector Memory T Cell Differentiation in Chronic Infection.

Authors:  Michael M Opata; Robin Stephens
Journal:  Curr Immunol Rev       Date:  2013-08

10.  Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis.

Authors:  Gajalakshmi Dakshinamoorthy; Gnanasekar Munirathinam; Kristen Stoicescu; Maryada Venkatarami Reddy; Ramaswamy Kalyanasundaram
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.